Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Benzinga01:12

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485299726?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1IYy6DehlWrM_QK5gaYrTw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/aafb09ec89647b56a691099922c789ab","is_english":true,"pubTime":"2024-11-23 01:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485299726","market":"us","top_or_hot":-1,"title":"Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook","media":"Benzinga","content":"<div>\n<p>Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/halozyme-withdraws-evotec-bid-rebuff-171258773.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 01:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/halozyme-withdraws-evotec-bid-rebuff-171258773.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/halozyme-withdraws-evotec-bid-rebuff-171258773.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"https://finance.yahoo.com/news/halozyme-withdraws-evotec-bid-rebuff-171258773.html","article_id":"2485299726","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1IYy6DehlWrM_QK5gaYrTw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/aafb09ec89647b56a691099922c789ab"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485299726","pubTimestamp":1732295578,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Halozyme Therapeutics, Inc.  saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE  for 11 euro  per share in cash, implying a fully diluted equity value of 2.0 billion euro.This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.The company expects revenue between $970 million and $1.02 billion  and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.Also Read: US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000. Helen Torley, CEO of Halozyme, explained that although the merger would","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗","EVO":"Evotec SE","BK4121":"生命科学工具和服务","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技"},"translate_title":"Halozyme在被拒绝后撤回Evotec收购，重申强劲的增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1,"EVO":0.9},"content_text":"Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share in cash, implying a fully diluted equity value of 2.0 billion euro.\nThis move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.\nIn addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.\nThe company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.\nHalozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.\nAlso Read: US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000\nHelen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.\nHalozyme’s efforts to engage with Evotec’s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.\n“A company spokesperson has publicly commented that its goal is to remain an independent company,” said Helen Torley, president and chief executive officer of Halozyme regarding Evotec, adding that “our multiple requests to meet were not accepted”.\n“Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,” Evotec said in a response.\nPrice Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.\nPhoto via Shutterstock\nRead Next:\n\n2025 US Economy Outlook’ Cloudier Than Normal,’ JPMorgan Says: Boom, Bust Scenarios\n\nUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.\nGet the latest stock analysis from Benzinga?\n\nEVOTEC (EVO): Free Stock Analysis Report\nHALOZYME THERAPEUTICS (HALO): Free Stock Analysis Report\n\nThis article Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485299726"}